Glycine is a basic amino acid widely used in the human body, and it simultaneously serves multiple roles as a protein building block, neurotransmitter, and metabolic intermediate. Based on existing human studies on sleep, metabolism, and the nervous system, its most practically valuable application is for sleep quality, as well as fatigue and alertness the day after sleep deprivation; common study protocols involve taking 3 g before bedtime.
Signals have also emerged in human studies regarding blood sugar, insulin, oxidative stress, and inflammation, but long-term clinical evidence is still insufficient. As for improving memory, anti-aging, increasing collagen, protecting joints, and boosting glutathione, although there are reasonable biological mechanisms, human evidence from pure glycine supplementation is far less certain than advertised.
What glycine is and what it does in the human body
1. Basic Properties
Glycine, called Glycine in English and グリシン in Japanese, has the chemical formula C₂H₅NO₂ and a molecular weight of about 75.07. It is the simplest of the 20 common protein amino acids, with a side chain consisting of only a single hydrogen atom, and is the only amino acid without chirality.
Glycine is usually classified as a non-essential amino acid, meaning that under normal circumstances, the human body can synthesize it on its own and does not need to rely entirely on dietary intake. However, "non-essential" does not mean it is unimportant. It participates in protein synthesis, collagen structure, glutathione (GSH) synthesis, creatine synthesis, as well as multiple metabolic pathways including purine and heme synthesis.
2. Two different roles as a neurotransmitter
In regions such as the spinal cord and brainstem, glycine can activate glycine receptors (GlyR). This receptor is a chloride ion channel and, when activated, generally decreases neuronal excitability. Therefore, glycine acts as an inhibitory neurotransmitter in these areas. This function is somewhat similar to GABA, but they correspond to different receptors.
Glycine is also one of the co-agonists required for normal NMDA receptor function. In addition to glutamate, NMDA receptors require glycine or D-serine to occupy the co-agonist site. Learning, memory, and synaptic plasticity all depend on normal NMDA receptor activity. This is also why psychiatric research has attempted to use high doses of glycine to improve NMDA function.
Currently, the most practically valuable human evidence: sleep
3. A small sleep study using 3 g at bedtime
A classic human study included 11 adults who had long-term dissatisfaction with their own sleep. Participants took 3 g of glycine before bedtime, and underwent polysomnography (PSG) monitoring. The results showed that participants' subjective sleep quality and sleep efficiency improved, and the time to fall asleep and reach slow-wave sleep was shortened.
It should be noted that the experiment observed faster entry into slow-wave sleep and did not find that the overall sleep structure was significantly altered. The proportions of REM, light sleep, and slow-wave sleep within the total sleep cycle were not substantially restructured. Therefore, a more accurate statement is that glycine may help the body enter sleep and slow-wave sleep more smoothly, rather than significantly increasing the total amount of deep sleep.
4. Fatigue, drowsiness, and cognitive performance the next day
The same study also found that taking 3 g of glycine before bed reduced daytime drowsiness the next day, and some memory recognition tests also showed improvement. This result is more likely due to improved sleep leading to better condition and test performance the next day, and cannot be directly interpreted as glycine itself enhancing memory.
Another study had healthy participants reduce their sleep time by 25% for three consecutive nights and then compared taking 3 g of glycine before bed with a placebo. The glycine group experienced significantly less fatigue the next day, showed a trend toward reduced drowsiness, and had improved reaction speed in psychomotor vigilance tasks (PVT). However, several tests such as simple reaction, memory recognition, and arithmetic did not show significant improvement, so the results cannot be generalized to the overall enhancement of next-day cognitive abilities.
5. Possibly helps with sleep through temperature regulation
Existing mechanistic studies do not support glycine suppressing the entire brain like typical sleeping pills. A more likely pathway is that oral glycine participates in NMDA receptor-related activity, affects the suprachiasmatic nucleus (SCN), promotes peripheral vasodilation and heat dissipation, lowers core body temperature, and thereby helps initiate sleep. The SCN is one of the core regions of the human circadian rhythm system.
When a person is preparing to sleep, blood flow to the hands and feet increases, transferring internal body heat to the periphery, and then the core body temperature gradually decreases. This is naturally part of the sleep initiation process. Glycine's role may not be simple sedation, but rather helping the body enter a physiological state that is more conducive to sleep more quickly.
The sleep deprivation experiment also measured melatonin, and the results showed no significant changes. Therefore, the current findings are more inclined to relate to temperature regulation and SCN-associated neural activity rather than promoting sleep by increasing melatonin; the physiological logic of glycine is not the same as that of melatonin.
6. The most common dosage in sleep studies
Currently, the most classic and repeatedly used protocol is taking 3 g about 30–60 minutes before bedtime, not 300 mg, and not 30 g. Relevant functional foods in Japan also use 3.0 g of glycine per day as the functional ingredient dosage, and their functional claims involve faster entry into deep sleep, improved sleep quality, feeling refreshed upon waking, reduced daytime sleepiness and fatigue, and helping to maintain work efficiency.
Functional foods are not equivalent to individually approved drugs and are not used for diagnosing, treating, or preventing diseases. Glycine can be discussed as a sleep health supplement, but it should not therefore be regarded as an officially approved insomnia treatment drug.
7. Main limitations of sleep evidence
The sample size of glycine sleep studies is very small; the most classic PSG study included only 11 participants. Some core studies involved researchers associated with Ajinomoto, and the first author of the 2012 sleep deprivation study also came from Ajinomoto Frontier Research Labs. This does not mean the experimental results are invalid, but it does indicate that the results still need to be replicated in larger-scale, longer-term, and fully independent studies.
What can be confirmed at present is that in small-scale experiments, people with tendencies toward unsatisfactory sleep showed improvements in some subjective and objective sleep indicators after short-term administration of 3 g. Existing research has not yet involved hundreds to thousands of patients clearly diagnosed with insomnia, and there is also a lack of multicenter, long-term treatment, relapse rate, and long-term efficacy data. Therefore, there is preliminary evidence for sleep assistance, but insufficient evidence for chronic insomnia treatment.
How cognitive and psychiatric research should understand it
8. Glycine is not equivalent to a direct 'memory enhancer.'
NMDA receptors are closely related to learning, memory, and long-term potentiation (LTP), and glycine is a co-agonist of this receptor. Therefore, it is easy to draw the inference that "supplementing glycine can enhance memory." The actual human response is much more complex, and there is currently no reliable large-scale trial evidence showing that taking 3 g of glycine daily can improve memory or intelligence in healthy people over the long term.
Studies in healthy adults have used a single high dose of 0.8 g/kg. For a body weight of 70 kg, this is equivalent to taking 56 g at once. This dosage has not been proven to comprehensively enhance cognitive ability; some experiments have even observed negative effects on sensorimotor gating and certain cognitive performances. More glycine does not necessarily lead to better cognitive effects.
9. Very High Doses in Schizophrenia Research
There is a hypothesis of NMDA receptor hypofunction in schizophrenia research, so some studies have tried to enhance NMDA function using very high doses of glycine. One double-blind crossover trial included 22 patients with treatment-resistant schizophrenia, using a daily dose of 0.8 g/kg, averaging about 60 g, for 6 weeks. After adding glycine, PANSS negative symptoms and BPRS total scores both improved by about 30%, indicating that the central mechanism between glycine and NMDA is not purely theoretical.
Subsequent results are not entirely consistent. Studies combining high-dose glycine with clozapine did not find benefits; the clozapine-only group actually improved more, leading researchers to suggest that high-dose glycine may interfere with clozapine efficacy. Daily doses of 50–60 g belong to medical research doses under special disease conditions and should not be taken as a common health supplement, nor should they be replicated on one's own.
For healthy people, the more reliable explanation at present is that after improved sleep, fatigue decreases the next day, and performance on some vigilance tasks may improve accordingly. It acts more like indirectly helping the next day's condition through sleep rather than being a well-evidenced direct cognitive enhancer.
Blood Glucose, Insulin, and Oxidative Stress
10. Acute Blood Glucose and Insulin Response
A human metabolism experiment compared the differences between co-ingestion of glycine with glucose and ingestion of glucose alone. With co-ingestion, the area under the plasma glucose curve decreased by more than 50%, while the insulin response increased, suggesting that glycine promotes insulin secretion.
Another experiment tested a single 5 g dose of glycine in healthy individuals with a first-degree relative history of type 2 diabetes. The subjects' early, late, and total insulin responses all increased, but insulin action or insulin sensitivity did not significantly change. Acute promotion of insulin secretion and long-term improvement of insulin sensitivity are two different matters and should not be confused.
11. Daily 15 g, 3-Month Metabolic Study
A randomized controlled trial included 60 patients with metabolic syndrome, with 30 taking glycine and 30 taking a placebo. The glycine group took a total of 15 g per day, divided into 5 g three times daily for 3 months.
The study used TBARS as an indicator of lipid peroxidation and oxidative stress. In the glycine group, it decreased by about 25% compared to the placebo group, and changes were also observed in redox system markers such as SOD, G6PD, and S-nitrosylated hemoglobin. This provides a line of human evidence for glycine in antioxidant and oxidative stress regulation worthy of further research.
In the same experiment, there was a significant decrease in systolic blood pressure in the male glycine group, with a statistical result of p=0.043. However, this is only the result of a specific gender subgroup and does not mean everyone can have a significant blood pressure reduction. The existing evidence is far from enough to call glycine a blood pressure-lowering supplement.
12. Changes in Inflammatory Markers Are Not Equivalent to Disease Treatment
In studies of people with type 2 diabetes, long-term intake of glycine led to changes in inflammatory or immune markers such as IL-6, IL-1β, TNF-related signals, and resistin, suggesting that glycine may have immune-regulating and anti-inflammatory effects.
Improvement in biomarkers does not equal improvement in clinical disease outcomes. A decrease in a certain inflammation marker does not automatically infer a significant reduction in cardiovascular disease risk, longer lifespan, or treatment of diabetes; these more important endpoints have not yet been truly proven.
Glutathione, collagen, muscle, and anti-aging
13. Evidence boundaries of glutathione and GlyNAC
Glutathione (GSH) is composed of three amino acids: glutamate, cysteine, and glycine; therefore, glycine is indeed one of the precursors for glutathione synthesis. If glycine is insufficient in the body, supplementing glycine could theoretically help GSH synthesis.
In recent years, some impressive “anti-aging” results have come from GlyNAC, which is a combination of glycine and N-acetylcysteine (NAC). Older adults using GlyNAC showed improvements in multiple indicators including GSH, oxidative stress, mitochondrial function, inflammation, insulin resistance, cognition, body fat, and muscle function.
These results cannot all be attributed to glycine. Cysteine provided by NAC is also an important precursor for glutathione, and in many cases may be the limiting factor for GSH synthesis. The effectiveness of GlyNAC only indicates that this combination may be effective, and does not prove that taking 3 g of glycine alone would produce exactly the same anti-aging, mitochondrial, cognitive, or body fat effects.
14. Rich collagen does not equal pure glycine improving skin and joints
Glycine is a very abundant amino acid in collagen. The typical collagen triple helix contains a large amount of the Gly-X-Y repeating structure, so it is indeed important for collagen structure. However, the fact that collagen contains a lot of glycine does not mean that taking glycine alone has been proven to improve skin or joints.
Existing typical skin randomized controlled trials use 2.5 g or 5 g of hydrolyzed collagen per day, rather than pure glycine; some other tendon or collagen synthesis studies use gelatin plus vitamin C, or collagen peptides, also not pure glycine. Collagen peptides, besides glycine, also contain proline, hydroxyproline, alanine, and various bioactive peptides, so the effects of collagen peptides cannot be equated with the effects of the same weight of pure glycine.
To date, skin elasticity, wrinkles, joint, and tendon repair cannot be considered functions that have strong randomized controlled trial evidence for pure glycine. These areas have strong biological plausibility, but direct human evidence is weak.
15. Muscle Growth and Special Disease Populations
Glycine is not a very strong amino acid for stimulating muscle protein synthesis; leucine and essential amino acids have more direct evidence in this regard. In one study of trainees given a single dose of 0.3 g/kg glycine, no significant improvement in upper or lower limb strength was found. Therefore, glycine cannot be used as a protein powder-type muscle-building product solely based on its amino acid identity.
In chronic hemodialysis patients with protein-energy wasting, a daily dose of 14 g glycine, divided into 7 g twice daily, for 4 consecutive months, showed improvement signals in fat-free mass index and grip strength. These subjects were malnourished patients with chronic kidney disease, so the results cannot be directly applied to healthy, fitness-oriented adults.
16. Animal Longevity Studies and the Gap to Human Evidence
A 2019 mouse study found that supplementing glycine in the diet extended the lifespan of both male and female mice, so glycine and longevity do have some scientific research basis. However, there is currently no human trial in which thousands of people have taken glycine continuously for years and ultimately demonstrated reduced mortality.
Lifespan extension in mice at this stage can only be regarded as a mechanistic clue and a direction for further research, and cannot be promoted as evidence that taking glycine can prolong human life. There is still a large gap between animal results and long-term human clinical outcomes.
Safety, dosage, and practical use
17. Short-term tolerability
The daily 3 g dose used in sleep studies has generally been well tolerated in existing small human trials. In another acute safety study of 12 healthy individuals, a single daytime intake of 9 g did not result in serious adverse reactions or noticeable daytime sleepiness.
Schizophrenia studies have used up to 0.8 g/kg per day, with some participants actually taking 50–60 g or more daily, and short-term overall tolerability was observed in some studies. However, short-term tolerability in medical research does not equal the safety of healthy people taking 60 g daily long-term, especially since high-dose experiments in healthy individuals have shown negative cognitive and sensory gating outcomes. There is no reason to pursue such doses for general health.
18. If the goal is only sleep
To align with the most direct current human studies, the clearest protocol is 3 g, 30–60 minutes before bedtime. Whether 500 mg, 1 g, 6 g, or 10 g is better or worse currently lacks high-quality dose-response randomized controlled trials. 3 g being effective does not mean that 6 g will double the effect.
- Do not self-administer high doses used in medical research: 50–60 g daily is not a general health regimen.
- Do not replace professional medical care: For chronic insomnia, significant daytime functional impairment, or suspected sleep disorders, professional evaluation should be sought.
- Consider medication and disease background: People taking prescription drugs such as clozapine, or those with chronic kidney disease, diabetes, and other conditions, should not copy study doses on their own.
- Manage expectations: Current evidence is closer to mild sleep support and does not support comprehensive cognitive enhancement or treatment of multiple chronic diseases.
Strength of evidence depends on the intended use.
The following scores are used to intuitively summarize the human evidence for pure glycine compiled in this article and are not the official ratings of any institution. Higher scores indicate relatively clearer research signals and do not equate to proven disease treatment.
- Improves subjective sleep quality: 7/10
- Reduces time to fall asleep or reach slow-wave sleep: 7/10
- Improves next-day fatigue: 6.5/10
- Improves alertness after sleep deprivation: 6/10
- Directly enhances memory in healthy individuals: 3/10
- Long-term concentration improvement: 3/10
- Regulates acute blood sugar response: 6.5/10
- Promotes insulin secretion: 7/10
- Long-term improvement of insulin resistance: 5/10
- Reduces oxidative stress: 6/10
- Anti-inflammatory effect: 5.5/10
- Improves blood pressure: 4/10
- Increases glutathione: 5/10, insufficient evidence when used alone
- Improves skin or collagen: 3/10, direct human evidence insufficient
- Joint or tendon effects: 3/10
- Muscle gain or strength enhancement: 2.5/10
- Extends human lifespan: 1/10
- Animal anti-aging mechanisms: 7/10
- Short-term safety of 3 g daily: 9/10
- Overall human evidence quality: 5.5–6/10
Conclusion
Glycine is not an unidentified mysterious substance, but a fundamental member of the human metabolic system. It has clear receptor actions, including GlyR and NMDA; is involved in collagen structure, glutathione and creatine synthesis, and is also related to sleep physiology involving the SCN and body temperature regulation, with a very clear biological basis.
Its rich mechanisms also make it easy to be marketed as a "miracle amino acid that can improve everything." Current human studies do not support this level of promotion. The most practical use worth remembering is still to take 3 g 30–60 minutes before bedtime. It may improve subjective sleep quality, help people fall asleep or enter slow-wave sleep faster, and reduce next-day fatigue and part of the alertness decline caused by insufficient sleep.
The limitations of this sleep evidence are also clear: trial samples are very small, and some core studies come from teams related to Ajinomoto. Taking 15 g daily for 3 months in populations with metabolic syndrome or diabetes showed improvements in oxidative stress, inflammation, and some metabolic indicators, but results are not consistent enough to be considered a mature treatment for diabetes or cardiovascular conditions.
Two common misconceptions must also be clarified: results from GlyNAC studies cannot be equated with glycine alone for anti-aging, because GlyNAC also contains NAC; collagen supplementation studies cannot prove that pure glycine has the same skin and joint effects, because the studies used whole collagen peptides or gelatin.